West Pharmaceutical Services Inc.

2 days ago · marketbeat.com

West Pharmaceutical Services NYSE: WST reported third-quarter results that exceeded its expectations, driven by continued demand for high-value product components, including those used in GLP-1 therapies and biologics. The company raised its full-year revenue and adjusted earnings outlook following the quarter.

3 days ago · seekingalpha.com

West Pharmaceutical Services, Inc. (WST) Q3 2026 Earnings Call Transcript

3 days ago · zacks.com

WST reports strong Q3 earnings and revenue growth, fueled by high-value products and margin expansion, and raises its 2026 sales and earnings outlook.

4 days ago · zacks.com

Although the revenue and EPS for West Pharmaceutical (WST) give a sense of how its business performed in the quarter ended September 2026, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.

4 days ago · zacks.com

West Pharmaceutical Services (WST) came out with quarterly earnings of $2.66 per share, beating the Zacks Consensus Estimate of $2.18 per share. This compares to earnings of $1.96 per share a year ago.

4 days ago · prnewswire.com

Raising Full-Year Net Sales and Adjusted-Diluted EPS guidance EXTON, Pa., Oct. 29, 2026 /PRNewswire/ -- West Pharmaceutical Services, Inc. (NYSE: WST), a leading provider of innovative, high-quality injectable solutions and services, today announced its financial results for the third quarter of 2026.

5 days ago · zacks.com

Get a deeper insight into the potential performance of West Pharmaceutical (WST) for the quarter ended September 2026 by going beyond Wall Street's top-and-bottom-line estimates and examining the estimates for some of its key metrics.

6 days ago · zacks.com

WST's Q3 earnings may benefit from strong HVP demand, biologics and GLP-1 growth, but West Vantage weakness and the SmartDose divestiture could weigh on sales.

12 days ago · zacks.com

West Pharmaceutical???s biologics exposure, Annex 1 projects and delivery-device growth support prospects despite near-term headwinds.

14 days ago · prnewswire.com

EXTON, Pa., Oct. 19, 2026 /PRNewswire/ -- On October 19, 2026, the Board of Directors of West Pharmaceutical Services, Inc. (NYSE: WST), a global leader in innovative solutions for injectable drug administration, declared a fourth-quarter dividend of $0.26 per share on the Company's common stock, an 18% increase over the $0.22 per share paid in the prior quarter. This is the thirty-fourth consecutive annual increase in the Company's dividend.